Anti-inflammatory therapies are promising candidates for the prevention of brain injury following prolonged seizures (status epilepticus). Biomarkers for therapy monitoring are needed to translate these recent findings to the clinic. The aim of this thesis was to develop imaging methods that can be used to monitor anti-inflammatory therapies and monitor disease progression following prolonged seizures. In order to achieve these goals, the lithium-pilocarpine model was used as a model of status epilepticus and novel MRI imaging methods were employed. Various imaging approaches including: quantitative, structural, molecular and functional imaging were tested for their possible investigative utility as imaging biomarkers for neuroprotective therapies. Alongside this, two different anti-inflammatory therapies were tested for their effectiveness to alter brain injury following status epilepticus. This thesis demonstrates that molecular imaging has potential to monitor neuroprotective therapies. Surprisingly, there was little evidence that the anti-inflammatory therapies tested here had beneficial effects. However, this thesis shows that employing novel imaging approaches and automated analysis methods can enable accurate in vivo assessment of disease altering therapies.